With Nick Menzies and @lshtm-tbmod.bsky.social, our new modeling study estimated how reductions in donor funding could affect the economic burden of #TB on patients, especially among the poorest households journals.plos.org/plosmedicine...
In this modeling study, Allison Portnoy and colleagues investigate the potential impact of reduced international donor funding on the household economic burden of tuberculosis in low- and middle-income countries 🧪 #MedSky #TB
plos.io/4ryyBFX
Our recent modelling study found that the estimated impact of new TB vaccines depends on the efficacy to prevent infectious asymptomatic TB. Read more in our paper out now in @plosmedicine.org!
journals.plos.org/plosmedicine...
We know conflict & crises have severe repercussions for TB; health system disruptions, displacement, food insecurity... In our latest paper we examine the effects of war in Ukraine on engagement with a digital adherence tech by people w TB & health care workers journals.theunion.org/content/ijtl...
1/📢 In our new publication, we estimate that in 2022, 134 million people worldwide had a recent Mycobacterium tuberculosis (Mtb) infection and were at high risk of progressing to TB disease. Read the full paper in PLOS Medicine (tinyurl.com/mtbinfection). #TBSky
In this mathematical modeling study, Alvaro Schwalb and colleagues estimate the global burden of viable Mycobacterium tuberculosis—that which can cause disease and be transmitted—to help guide disease prevention efforts 🧪 #tuberculosis #MedSky
plos.io/4aqzIQV
Our new paper on strategies for implementing a potential new #TB #vaccine in South Africa is now published in @plosglobalpublichealth.org!
doi.org/10.1371/jour...
The TBMAC intro course is always a highlight of #UnionConf, and I loved being a tutor this year! We equipped a new audience with a clear understanding of how TB models are set up and what they can do to drive policy #EndTB #WCLH2025 #GlobalHealth
Interested in #TB, equity, and modelling? @reinhouben.bsky.social and I are advertising an MRC LID studentship on heterogeneity in the coverage of community screening for TB @lshtm-tbmod.bsky.social @lshtm.bsky.social.
For more details, visit mrc-lid.lshtm.ac.uk/2026-27-proj...
What’s a #UnionConf without the TB modelling course? Packed room again for a long day of intro to modelling.
@lshtm-tbmod.bsky.social @tb-mac.bsky.social #WCLH2025 #TBSky
@lshtm-tbmod.bsky.social is offering multiple PhD opportunities through MRC LID, deadline 14 Jan. More details: mrc-lid.lshtm.ac.uk/applicants/
Projects include
#1 TB & screening
#2 TB & climate change
#3 TB & vaccines
#4 TB & influenza
#5 TB & prevention
@cmmid-lshtm.bsky.social @lshtm.bsky.social
Perhaps the most important collaboration at #UnionConf2025?
WHO STOP TB’s Hello Kitty met the LSHTM TB Modelling Group’s bunny mascot “Bugs” today 🐰
Shout out to @stoptb.bsky.social and @lshtm-tbmod.bsky.social for making TB epidemiology both rigorous and accessible. #EndTB #WCLH2025
The keynote of #UnionConf2025 reminded us why we’re all here.
Author @johngreensbluesky.bsky.social & TB survivor Henry Rider delivered an impassioned call to action, centering lived experiences and fairness as drivers of new research.
This week is about science AND solidarity #EndTB #WCLH2025
Come join the @lshtm-tbmod.bsky.social for a PhD!
Our framework that informed the @who.int TB & climate change policy brief out now in @lancetrespirmed.bsky.social, exploring the intersections and implications of climate change for the TB epidemic. Key message? TB should be considered a climate-sensitive disease
www.thelancet.com/journals/lan...
“Wow, I saw in the last GTB report undernutrition is much less important for TB than we previously thought” I hear you say…
Well, no. We think this is an underestimate, & as much as 28% of TB could be attributable to undernutrition – see our latest comment here: www.thelancet.com/journals/lan...
When fluoroquinolone resistance status is unknown, empirical use of BPaLM (adding moxifloxacin to BPaL) is cost-effective as a replacement for BPaL even with high fluoroquinolone resistance levels! 🦠💊
doi.org/10.1371/jour...
Nutritional status is a key determinant of TB. In this updated systematic review and dose-response meta-analysis (43 cohorts inc > 26 million people) we redefined the relationship between body mass index (BMI) and TB. doi.org/10.1093/ije/...
At a time when global resources for #TB research, development, prevention, and care are limited, which interventions should be prioritised in high burden settings?
📢 Our new pre-print compares the impact, cost, and cost-effectiveness of 9 TB interventions in 3 countries. 1/n
bit.ly/3V3vXth
📯 New research from @kchorton.bsky.social and colleagues from @lshtm-tbmod.bsky.social!
#TB incidence can rebound after community screening ends, meaning the gains made during a program can be erased in the years that follow. This highlights a major challenge in sustaining impact #EndTB #EpiSky
Scientists’ role in defending democracy
www.science.org/doi/10.1126/...
Our work estimating the potential impacts of reductions in international donor funding for #TB is now out in @lancetgh.bsky.social:
bit.ly/3TDl28T
@raclark18.bsky.social @cfmcquaid.bsky.social @alexandra-richards.bsky.social @top-j.bsky.social @reinhouben.bsky.social @richardwhite321.bsky.social
Our new study examines social contact patterns in urban, peri-urban, and rural communities and their implications for #TB interventions like household contact tracing, infection prevention, and cluster RCTs. #MedSky #EpiSky #IDsky #TBSky
Read more in @plosglobalpublichealth.org
Great op-ed @usatoday.com from longtime TB Fighter Quinn Yates: www.usatoday.com/story/opinio...
New systematic review led by @hannahrickman.bsky.social shows annual risk of Mycobacterium #tuberculosis conversion in men and women diverges during adolescence and remains higher among men throughout adulthood.
www.thelancet.com/journals/lan...
Figure 1. Estimated number of trial endpoints in the control group of a prevention-of-disease vaccine trial in a high disease-burden setting showing number of endpoints on the y-axis and time in months on the x-axis. For bacteriologically confirmed symptomatic tuberculosis disease endpoints only, we estimate 69 endpoints, and for combined bacteriologically confirmed asymptomatic and symptomatic tuberculosis disease endpoints, we estimate 151 endpoints. Scenario assumes symptomatic disease incidence before trial screening of 300/100 000 per year and following 10 000 individuals over 3 years. Prevalent symptomatic and asymptomatic tuberculosis disease are screened out in month 0 and are not trial endpoints. Active screening occurs every 6 months for both scenarios and participants self-presenting with symptoms suggestive of tuberculosis disease would also be investigated.
In our latest personal view in @lancetrespirmed.bsky.social, we argue for the inclusion asymptomatic #tuberculosis in vaccine trial endpoints to potentially reduce the size, length, and cost of trials.
doi.org/10.1016/S221...
@lshtm-tbmod.bsky.social @tb-lshtm.bsky.social
Tuberculosis still kills around 1.3 million people every year.
It was once a massive killer in Europe and the US, but not anymore. How did these countries manage to tackle it?
Our first article on TB in a three-part series: ourworldindata.org/tuberculosis...
TB & climate change: @who.int report out now, building on an analytical framework we developed to explore the intersections and implications for the TB epidemic. Key message? TB should be considered a climate-sensitive disease www.who.int/publications...
Can you believe it’s already been 25 years!?
Come join us on 20 June 2025 at 4pm UK time to celebrate the 25th anniversary of the Introduction to #Infectious Disease #Modelling course delivered by @lshtm.bsky.social and @ukhsa.bsky.social!
More info 👉 www.lshtm.ac.uk/newsevents/e...
The chest x-ray use pioneered by Alan Hart continues to be extremely important in screening for tuberculosis. Although no one accomplishes anything in isolation, I'd argue that Hart has helped saved MILLIONS of lives because chest x-rays have been so essential in driving down rates of TB globally.
